Jazz Pharmaceuticals announced the appointment of Thomas Riga as Chief Business Officer, effective January 1, 2026. Mr. Riga joined Jazz in April 2025 through the acquisition of Chimerix Inc., where he served as Chief Operating and Commercial Officer. During his tenure at Chimerix, he led the regulatory strategy and U.S. approval of the first therapy for H3K27M-mutant diffuse midline glioma, a disease affecting roughly 2,000 children and young adults annually. Over his 25-year career in the pharmaceutical industry, he has overseen sales and marketing, operations and business development, executing over $2 billion in transactions in the last five years. In his new role, Mr. Riga will lead Jazz’s corporate development initiatives and strategic partnerships to expand the company’s portfolio of innovative medicines.

Jazz Pharmaceuticals released positive Phase 3 data for zanidatamab-hrii (Ziihera) combined with anti-PD-1 antibody tislelizumab and chemotherapy in patients with HER2-positive gastroesophageal adenocarcinoma. The triplet regimen achieved a median overall survival of 26.4 months, marking the longest survival reported to date in a Phase 3 GEA study and representing a 28% reduction in risk of death versus standard chemotherapy. The doublet combination of Ziihera and chemotherapy also delivered strong results, with a median overall survival of 24.4 months. Following the announcement, Jazz’s shares rose by 2.07%, reflecting investor confidence in the therapy’s potential to become a new standard of care for this patient population.